SOURCE: Levi & Korsinsky, LLP
NEW YORK, NY--(Marketwired - Jan 29, 2014) - Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased Aegerion Pharmaceuticals, Inc. ("Aegerion" or the "Company") (NASDAQ: AEGR) securities between March 15, 2012 and January 9, 2014.
For more information, click here: http://zlk.9nl.com/aegerion-pharmaceuticals-aegr.
The complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (a) the Company marketed its drugs in violation of the Federal Food Drug and Cosmetic Act; (b) as a result of these violations, the Company exposed itself to heightened regulatory scrutiny by the FDA and other governmental bodies; (c) as a result of the aforementioned, Aegerion's statements regarding the Company's business, operations, and prospects were materially false and misleading.
On January 10, 2014, Aegerion received a subpoena from the U.S. Department of Justice requesting documents relating to the marketing and sale of the Company's JUXTAPID capsules. Upon this news, shares of Aegerion fell almost 11% to close at $65.77 per share.
If you suffered a loss in Aegerion you have until March 17, 2014 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/aegerion-pharmaceuticals-aegr.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.